Oral pamidronate prevents high-dose glucocorticoid-induced lumbar spine bone loss in premenopausal connective tissue disease (mainly lupus) patients.
(2005) Lupus — Vol. 14, n° 7, p. 517-520 (2005)
Files
10313.pdf
Restricted Access - Adobe PDF
- 1.12 MB
Details
- Authors
- Abstract
- Glucocorticoid (GC)-induced osteoporosis contributes to chronic damage in patients suffering from connective tissue diseases (CTD) such as systemic lupus erythematosus (SLE). In this study, performed in an highly selected cohort of premenopausal female CTD (mostly lupus) patients, given high-dose GC therapy for severe disease, we show that lumbar spine bone loss can be averted by treatment with oral disodium pamidronate combined with calcium salts and vitamin D3 supplements and not by calcium salts and vitamin D3 supplements alone. We stress the need for optimal GC-induced bone loss prevention therapy in premenopausal patients, a too often neglected issue in patients whose survival has dramatically improved over the last decades.
- Affiliations
Citations
Nzeusseu Toukap, A., Depresseux, G., Devogelaer, J.-P., & Houssiau, F. (2005). Oral pamidronate prevents high-dose glucocorticoid-induced lumbar spine bone loss in premenopausal connective tissue disease (mainly lupus) patients. Lupus, 14(7), 517-520. https://doi.org/10.1191/0961203305lu2149oa (Original work published 2005)